Javascript must be enabled to continue!
HDAC6 promotes hepatocellular carcinoma progression by inhibiting P53 transcriptional activity
View through CrossRef
Hepatocellular carcinoma (HCC) is the most common type of liver cancer. HDAC6 is a transcriptional regulator of the histone deacetylase family, subfamily 2. Previous studies have shown that HDAC6 plays critical roles in transcription regulation, cell cycle progression and developmental events. However, its biological roles in the development of HCC remain largely unexplored. In the present study, we found that mRNA and protein levels of HDAC6 were up‐regulated in HCC tissues and cell lines. The proinflammatory cytokines, which were up‐regulated in the human HCC microenvironment, increased HDAC6 expression through a proximal NF‐kappaB binding site on the HDAC6 gene promoter. Furthermore, overexpression of HDAC6 could promote cell proliferation in HCC cell lines. In contrast, HDAC6 knockdown using small interfering RNA inhibited cell proliferation. At the molecular level, we demonstrated that HDAC6 could interact with p53 and attenuate its transcriptional activity through promotion of its degradation. Therefore, our results suggest a previously unknown HDAC6‐p53 molecular network controlling HCC development.
Title: HDAC6 promotes hepatocellular carcinoma progression by inhibiting P53 transcriptional activity
Description:
Hepatocellular carcinoma (HCC) is the most common type of liver cancer.
HDAC6 is a transcriptional regulator of the histone deacetylase family, subfamily 2.
Previous studies have shown that HDAC6 plays critical roles in transcription regulation, cell cycle progression and developmental events.
However, its biological roles in the development of HCC remain largely unexplored.
In the present study, we found that mRNA and protein levels of HDAC6 were up‐regulated in HCC tissues and cell lines.
The proinflammatory cytokines, which were up‐regulated in the human HCC microenvironment, increased HDAC6 expression through a proximal NF‐kappaB binding site on the HDAC6 gene promoter.
Furthermore, overexpression of HDAC6 could promote cell proliferation in HCC cell lines.
In contrast, HDAC6 knockdown using small interfering RNA inhibited cell proliferation.
At the molecular level, we demonstrated that HDAC6 could interact with p53 and attenuate its transcriptional activity through promotion of its degradation.
Therefore, our results suggest a previously unknown HDAC6‐p53 molecular network controlling HCC development.
Related Results
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
Abstract 1176: Bypassing the dominant-negative effect of mutant p53 in cancer cells
Abstract 1176: Bypassing the dominant-negative effect of mutant p53 in cancer cells
Abstract
The tumor suppressor p53 is mutated in more than 50% of all cancers. The transcriptional activity of p53 depends on localization to the nucleus and formatio...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Role of HDAC6 in Skeletal Muscle Atrophy
Role of HDAC6 in Skeletal Muscle Atrophy
Rôle de l’Histone Deacetylase 6 au cours de l’atrophie musculaire
HDAC6 est une histone déacétylase hautement conservée, principalement cytoplasmique. Contrairement...
Abstract 599: Id4 acts as a tumor suppressor by inducing apoptosis and senescence in p53-dependent manner
Abstract 599: Id4 acts as a tumor suppressor by inducing apoptosis and senescence in p53-dependent manner
Abstract
The physiological mechanisms that can restore biological activity of mutant p53 is an area of high interest given that mutant p53 expression is observed in ...
Abstract 1706: Investigating the interaction between ETS family members and mutant p53
Abstract 1706: Investigating the interaction between ETS family members and mutant p53
Abstract
Cancer cases are on the rise globally requiring a deeper understanding of the disease and identification of novel therapeutic targets. Mutations in genes of...
High P53 Protein Expression Level Independent of Mutational Status Is An Adverse Prognostic Factor for Survival in Acute Myeloid Leukemia
High P53 Protein Expression Level Independent of Mutational Status Is An Adverse Prognostic Factor for Survival in Acute Myeloid Leukemia
Abstract
Abstract 1490
Background:
The tumor suppressor p53 is frequently mutated in human cancer, including acut...
Jun Dimerization Protein 2 (JDP2) Increases p53 Transactivation by Decreasing MDM2
Jun Dimerization Protein 2 (JDP2) Increases p53 Transactivation by Decreasing MDM2
The AP-1 protein complex primarily consists of several proteins from the c-Fos, c-Jun, activating transcription factor (ATF), and Jun dimerization protein (JDP) families. JDP2 has ...

